Literature DB >> 17072957

Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past.

Roberto Santambrogio1, Enrico Opocher, Mara Costa, Savino Bruno, Andrea Pisani Ceretti, Gian Paolo Spina.   

Abstract

AIM: To compare endoscopic sclerotherapy (ES) with distal splenorenal shunt (DSRS) in the prevention of recurrent variceal bleeding in cirrhotic patients during a long-term follow-up period.
METHODS: In 1984 we started a prospective, controlled study of patients with liver cirrhosis. Long-term follow-up presents a natural history of liver cirrhosis complicated by advanced portal hypertension. In this study the effects of 2 types of treatment, DSRS or ES, were evaluated. The study population included 80 patients with cirrhosis and portal hypertension referred to our department from October 1984 to March 1991. These patients were drawn from a pool of 282 patients who underwent either elective surgery or ES during the same period of time. Patients were assigned to one of the 2 groups according to a random number table: 40 to DSRS and 40 to ES using polidocanol.
RESULTS: During the postoperative period, no DSRS patient died, while one ES patient died of uncontrolled hemorrhage. One DSRS patient had mild recurrent variceal hemorrhage despite an angiographically patent DSRS and another patient suffered duodenal ulcer rebleeding. Eight ES patients suffered at least one episode of gastrointestinal bleeding: 4 from varices and 4 from esophageal ulcerations. Eight ES patients developed transitory dysphagia. Long-term follow-up was completed in all patients except for 5 cases (2 DSRS and 3 ES patients). Five-year survival rates for shunt (73%) and ES (56%) groups were statistically different: in this follow-up period and in subsequent follow-ups this difference decreased and ceased to be of statistical relevance. The primary cause of death became hepatocellular carcinoma (HCC). Four DSRS patients rebled due to duodenal ulcer, while eleven ES patients had recurrent bleeding from esophago-gastric sources (seven from varices, three from hypertensive gastropathy, one from esophageal ulcerations) and two from unknown sources. Nine DSRS and 2 ES patients developed a chronic encephalopathy; 13 DSRS and 5 ES patients suffered at least one episode of acute encephalopathy. Five ES patients had esophageal stenoses, which were successfully dilated.
CONCLUSION: In a subgroup of patients with good liver function, DSRS with a correct portal-azygos disconnection more effectively prevents variceal rebleeding than ES. However, this positive effect did not influence the long-term survival because other factors (e.g. HCC) were more important in deciding the fate of the cirrhotic patients with portal hypertension.

Entities:  

Mesh:

Year:  2006        PMID: 17072957      PMCID: PMC4088142          DOI: 10.3748/wjg.v12.i39.6331

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  41 in total

1.  A prospective, randomized controlled trial of chronic esophageal variceal sclerotherapy.

Authors:  J Korula; L A Balart; G Radvan; B E Zweiban; A W Larson; H W Kao; S Yamada
Journal:  Hepatology       Date:  1985 Jul-Aug       Impact factor: 17.425

2.  Results of a modified distal spleno-renal shunt for portal hypertension.

Authors:  J Vang; G Simert; J A Hansson; U Thylen; T S Bengmark
Journal:  Ann Surg       Date:  1977-02       Impact factor: 12.969

3.  A prospective randomized study of two sclerotherapy techniques for esophageal varices.

Authors:  D Westaby; B R Macdougall; W Melia; A Theodossi; R Williams
Journal:  Hepatology       Date:  1983 Sep-Oct       Impact factor: 17.425

Review 4.  The distal splenorenal shunt: an update.

Authors:  J M Henderson; W J Millikan; W D Warren
Journal:  World J Surg       Date:  1984-10       Impact factor: 3.352

5.  Angiography in portal hypertension: clinical significance in surgery.

Authors:  B M Nordlinger; D F Nordlinger; J T Fulenwider; W J Millikan; P J Sones; M Kutner; R Steele; R Bain; W D Warren
Journal:  Am J Surg       Date:  1980-01       Impact factor: 2.565

6.  The course of patients after variceal hemorrhage.

Authors:  D Y Graham; J L Smith
Journal:  Gastroenterology       Date:  1981-04       Impact factor: 22.682

7.  Failure of repeated injection sclerotherapy to improve long-term survival after oesophageal variceal bleeding. A five-year prospective controlled clinical trial.

Authors:  J Terblanche; P C Bornman; D Kahn; M A Jonker; J A Campbell; J Wright; R Kirsch
Journal:  Lancet       Date:  1983-12-10       Impact factor: 79.321

8.  Ten years portal hypertensive surgery at Emory. Results and new perspectives.

Authors:  W D Warren; W J Millikan; J M Henderson; L Wright; M Kutner; R B Smith; J T Fulenwider; A A Salam; J T Galambos
Journal:  Ann Surg       Date:  1982-05       Impact factor: 12.969

9.  Improved survival following injection sclerotherapy for esophageal varices: final analysis of a controlled trial.

Authors:  D Westaby; B R Macdougall; R Williams
Journal:  Hepatology       Date:  1985 Sep-Oct       Impact factor: 17.425

10.  Sclerotherapy after first variceal hemorrhage in cirrhosis. A randomized multicenter trial.

Authors: 
Journal:  N Engl J Med       Date:  1984-12-20       Impact factor: 91.245

View more
  6 in total

1.  Hypersplenism is correlated with increased risk of hepatocellular carcinoma in patients with post-hepatitis cirrhosis.

Authors:  Xing Lv; Fan Yang; Xin Guo; Tao Yang; Ti Zhou; Xiaoping Dong; Yong Long; Dan Xiao; Yong Chen
Journal:  Tumour Biol       Date:  2016-01-11

2.  Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis.

Authors:  Danielle Roberts; Lawrence Mj Best; Suzanne C Freeman; Alex J Sutton; Nicola J Cooper; Sivapatham Arunan; Tanjia Begum; Norman R Williams; Dana Walshaw; Elisabeth Jane Milne; Maxine Tapp; Mario Csenar; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-04-10

3.  Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis.

Authors:  Maria Corina Plaz Torres; Lawrence Mj Best; Suzanne C Freeman; Danielle Roberts; Nicola J Cooper; Alex J Sutton; Davide Roccarina; Amine Benmassaoud; Laura Iogna Prat; Norman R Williams; Mario Csenar; Dominic Fritche; Tanjia Begum; Sivapatham Arunan; Maxine Tapp; Elisabeth Jane Milne; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-03-30

4.  Prognostic value of site-specific metastases and therapeutic roles of surgery for patients with metastatic bladder cancer: a population-based study.

Authors:  Fan Dong; Yifan Shen; Fengbin Gao; Tianyuan Xu; Xianjin Wang; Xiaohua Zhang; Shan Zhong; Minguang Zhang; Shanwen Chen; Zhoujun Shen
Journal:  Cancer Manag Res       Date:  2017-11-14       Impact factor: 3.989

5.  What are the implications of the spontaneous spleno-renal shunts in liver cirrhosis?

Authors:  Giovanni Tarantino; Vincenzo Citro; Paolo Conca; Antonio Riccio; Marianna Tarantino; Domenico Capone; Michele Cirillo; Roberto Lobello; Vittorio Iaccarino
Journal:  BMC Gastroenterol       Date:  2009-11-24       Impact factor: 3.067

6.  Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis.

Authors:  Rosa G Simonetti; Giovanni Perricone; Helen L Robbins; Narendra R Battula; Martin O Weickert; Robert Sutton; Saboor Khan
Journal:  Cochrane Database Syst Rev       Date:  2020-10-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.